Enterprise Value
-36.76M
Cash
137.8M
Avg Qtr Burn
-17.91M
Short % of Float
5.79%
Insider Ownership
7.08%
Institutional Own.
47.04%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ECUR-506 Details Ornithine transcarbmylase deficiency | Phase 1/2 Data readout | |
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details Cancer, B-cell lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Update | |
PBCAR19B (CD19 Allogeneic CAR-T) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Update | |
PBCAR20A (targeting CD20) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia | Failed Discontinued | |
PBCAR269A (BCMA) Details Cancer, Multiple myeloma | Failed Discontinued |